Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity

Seo, Soo Hong; Han, Hee Dong; Noh, Kyung Hee; Kim, Tae Woo; Son, Sang Wook

doi:10.1007/s10585-008-9228-5

Cited by 73 publications

(43 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Water soluble chitosan oligomer has been reported to be able to inhibit the proliferation of human leukaemia HL-60 cells [35]. Also, chitin and chitosan are known to enhance the antitumour effect of cancer drugs [36][37][38][39][40][41]. The exact mechanism of action of chitin and derivatives is still unknown, but different mechanisms can be proposed:…”

Section: Discussionmentioning

confidence: 99%

Anticancer activity of chemically prepared shrimp low molecular weight chitin evaluation with the human monocyte leukaemia cell line, THP-1

Salah

Michaud

Mati

et al. 2013

International Journal of Biological Macromolecules

135

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anticancer activity of chemically prepared shrimp low molecular weight chitin evaluation with the human monocyte leukaemia cell line, THP-1

Salah

Michaud

Mati

et al. 2013

International Journal of Biological Macromolecules

135

View full text Add to dashboard Cite

“…Seo et al [122] formulated a novel biodegradable chitosan hydrogel, a co-delivery system for immunoadjuvants, and antineoplastic agents for advanced cancer therapy. The anticancer drugs (doxorubicin, cyclophosphamide, and cisplatin) along with GMCSF were incorporated and investigated against TC-1 cervical cells (expressing tumor-specific antigen HPV-16 E7) of mice to assess tumor growth.…”

Section: Localized Drug Delivery Systemsmentioning

confidence: 99%

“…No.Drug/therapy/functional groupType/Composition of gelCell lines /animal models/neoplasmReferences1.PaclitaxelPoly- N -isopropylacrylamide, tert-butyl 2-acrylamidoethyl carbamate and N -hydroxyethyl acrylamideMCF7, T47D, and HeLa cells[115]2.DoxorubicinFe 3 O 4 magnetic nanoparticle-incorporated poly-( N -isopropylacrylamide)-chitosan-based nanohydrogelsHeLa cells[116]3.Photothermal therapyHydrogel system containing polyacrylamide-based nanoparticlesHeLa cells[117]4.DoxorubicinCryogel formulations based on chitosan-gelatin, chitosan-agarose and chitosan-agarose gelatinHeLa cells[118]5.Arginine-glycine-aspartic acid-serineMagnetic iron oxide nanoparticles coated with polyethylene glycol hydrogelHeLa cells[119]6.5-fluorouracilPluronic F127 together with alternative mucoadhesive polymers, e.g. hyaluronic acid, Carbopol 934, and hydroxypropyl methylcelluloseHeLa cells[120]7.PaclitaxelTemperature-sensitive poly(organophosphazene)–PTX conjugateHeLa cells and nude mice[121]8.Doxorubicin, cyclophosphamide and cisplatinChitosan hydrogelMice containing TC-1 cervical cells[122]9.5-aminolevulinic acid (5-ALA) ester hexylamionolevulinatePoloxamer 407Cervical intraepithelial neoplasia[123,124] …”

Section: Localized Drug Delivery Systemsmentioning

confidence: 99%

Possible role of nanocarriers in drug delivery against cervical cancer

Gupta

2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Introduction: Cervical cancer is the second most common cancer and the largest cancer killer among women in most developing countries including India. Although, various drugs have been developed for cervical cancer, treatment with these drugs often results in a number of undesirable side effects, toxicity and multidrug resistance (MDR). Also, the outcomes for cervical cancer patients remain poor after surgery and chemo radiation. Methods: A literature search (for drugs and delivery systems against cervical cancer) was performed on PubMed and through Google. The present review discuss about various methods including its current conventional treatment with special reference to recent advances in delivery systems encapsulating various anticancer drugs and natural plant products for targeting towards cervical cancer. The role of photothermal therapy, gene therapy and radiation therapy against cervical cancer is also discussed. Results: Systemic/targeted drug delivery systems including liposomes, nanoparticles, hydrogels, dendrimers etc. and localized drug delivery systems like cervical patches, films, rings etc. are safer than the conventional chemotherapy which has further been proved by the several drug delivery systems undergoing clinical trials. Conclusion: Novel approaches for the aggressive treatment of cervical cancer will optimistically result in decreased side effects as well as toxicity, frequency of administration of existing drugs, to overcome MDR and to increase the survival rates.

show abstract

“…GS-9191, a nucleotide analog prodrug, shows the anti-proliferative effect in vitro , and its topical application reduces the size of papilloma in the cottontail rabbit papillomavirus model [56]. Chitosan hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with anticancer drugs, cyclophosphamide in particular, results in antitumor effects through CD8+ T cell immunity [57]. Heparin-like glycosaminoglycans inhibit tumor growth by downregulating HPV18 long control region activity in transgenic mice [58].…”

Section: Therapeutics Against Hpvsmentioning

confidence: 99%

Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer

Zhen

2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Oncogenic human papillomaviruses (HPVs) cause different types of cancer especially cervical cancer. HPV-associated carcinogenesis provides a classical model system for clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) based cancer therapies since the viral oncogenes E6 and E7 are exclusively expressed in cancerous cells. Sequence-specific gene knockdown/knockout using CRISPR/Cas9 shows promise as a novel therapeutic approach for the treatment of a variety of diseases that currently lack effective treatments. However, CRISPR/Cas9-based targeting therapy requires further validation of its efficacy in vitro and in vivo to eliminate the potential off-target effects, necessitates verification of the delivery vehicles and the combinatory use of conventional therapies with CRISPR/Cas9 to ensure the feasibility and safety. In this review we discuss the potential of combining CRISPR/Cas9 with other treatment options as therapies for oncogenic HPVs-associated carcinogenesis. and present our assessment of the promising path to the development of CRISPR/Cas9 therapeutic strategies for clinical settings.

show abstract

Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity

Abstract: Cancer

Cited by 73 publications

References 46 publications

Anticancer activity of chemically prepared shrimp low molecular weight chitin evaluation with the human monocyte leukaemia cell line, THP-1

Anticancer activity of chemically prepared shrimp low molecular weight chitin evaluation with the human monocyte leukaemia cell line, THP-1

Possible role of nanocarriers in drug delivery against cervical cancer

Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer

Contact Info

Product

Resources

About